Anavex Appoints Scientific Advisory Board Member with Expertise in Protein Misfolding Neurodegenerative Diseases

NEW YORK, NY –March 5, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Corinne Lasmézas, DVM, PhD, to the Company’s Scientific Advisory Board.…